MEDI-6469
- Generic Name
- MEDI-6469
- Drug Type
- Biotech
- CAS Number
- 1715924-11-0
- Unique Ingredient Identifier
- AKV2GM43DD
- Background
MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies).
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 4
- Registration Number
- NCT02559024
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Registration Number
- NCT01689870
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Phase 1
Completed
- Conditions
- Metastatic Prostate CancerCancer of the ProstateProstate Cancer
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 13
- Registration Number
- NCT01303705
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath